Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome and Catastrophic Antiphospholipid Syndrome

Cover Page


Cite item

Full Text

Abstract

Background: The role of the alternative complement pathway (AP) abnormalities in the pathogenesis of aHUS is well studied. Clinical and morphological manifestations of atypical HUS and catastrophic APS are often similar. However, studies on the state of AP in patients with CAPS are virtually absent. 

Aims: The aim of our study was to assess the state of AP in patients with CAPS and aHUS. Patients and methods: The study enrolled 67 patients (pts) with a diagnosis of CAPS (28 pts) and aHUS (39 pts). Studies of the complement system are made of 10 pts with CAPS and 20 aHUS. Factor H, I, B, D content, functional activity of factor H, and complement components C3, C4 was determined in serum by ELISA kit. 

Results: Patients with CAPS and aHUS showed similar changes in complement biomarkers. The factor H level in the serum was significantly higher than the standard value. However, the specific activity of factor H reduced, mean rate 59% for aHUS and 26% for CAPS. The median value of factor D was twice higher than the normal range in both groups, indicating the activation of the AP. 

Conclusions: There are indications of an AP activation not only in pts with aHUS but in CAPS pts too. We suppose that the activity of factor H is a more sensitive indicator of complement system changes than factor H level. Patients with CAPS and aHUS have similar clinical and laboratory characteristics. However, CAPS is more severe, with the involvement of a larger number of vascular beds. Perhaps this is due to the double damaging effects on the endothelium ― of antiphospholipid antibodies (aPL) and activated complement. So we hypothesize that CAPS can be called aPL-mediated TMA in pts with a complement system defect.

About the authors

K. A. Demyanova

Sechenov First Moscow State Medical University

Author for correspondence.
Email: ksedem@gmail.com
ORCID iD: 0000-0001-8927-5841

Аспирант кафедра нефрологии и гемодиализа института профессионального образования. 

SPIN-код: 5474-1091

Россия

N. L. Kozlovskaya

Sechenov First Moscow State Medical University

Email: nkozlovskaya@yandex.ru
ORCID iD: 0000-0002-4275-0315

Доктор медицинских наук, профессор кафедры нефрологии и гемодиализа института профессионального образования 

SPIN 1110-4764

Россия

L. A. Bobrova

Sechenov First Moscow State Medical University

Email: mrlee2005@ya.ru
ORCID iD: 0000-0001-6265-4091

Кандидат медицинских наук, старший научный сотрудник Научно-исследовательского отдела нефрологии НИЦ 

SPIN 7435-1504

Россия

L. V. Kozlov

G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: fake@neicon.ru
Доктор биологических наук, до марта 2016 г. ― профессор, руководитель группы  Россия

S. S. Andina

G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: andinasvetlana@rambler.ru
ORCID iD: 0000-0002-0284-3787

Кандидат биологических наук, старший научный сотрудник 

SPIN-код: 8479-9628

Россия

V. A. Yurova

Sechenov First Moscow State Medical University

Email: val84-05@mail.ru
ORCID iD: 0000-0002-7041-3391

Аспирант кафедры нефрологии и гемодиализа института профессионального образования 

SPIN-код: 3906-3609

Россия

A. M. Kuchieva

Sechenov First Moscow State Medical University

Email: agunda_81@mail.ru
ORCID iD: 0000-0002-8360-7734

Врач-нефролог отделения искусственная почка Университетской клинической больницы № 3 

SPIN-код: 3292-8178

Россия

S. V. Roshchupkina

Sechenov First Moscow State Medical University

Email: roschupkina.sv@yandex.ru
ORCID iD: 0000-0003-4695-1568

Зав.отделения нефрологии Университетской клинической больницы № 3, врач высшей категории

 SPIN-код: 4611-8464

Россия

E. M. Shilov

Sechenov First Moscow State Medical University

Email: emshilov@mma.ru
ORCID iD: 0000-0002-2111-191X

Доктор медицинских наук, профессор, заведующий кафедрой нефрологии и гемодиализа института профессионального образования

SPIN: 1538-9845

References

  1. Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, et al. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrología (English Edition). 2015; 35(5):421–47.doi.org/10.1016/j.nefroe.2015.11.006
  2. Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med. 2013;24(6):496–502.doi.org/10.1016/j.ejim.2013.05.009
  3. Hofer J, Rosales A, Fischer C, Giner T. Extra-Renal Manifestations of Complement-Mediated Thrombotic Microangiopathies. Front Pediatr. 2014 ;2 . doi.org/10.3389/fped.2014.00097
  4. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012; 8(11):622–33. doi.org/10.1038/nrneph.2012.195
  5. Cervera R, Bucciarelli S, Plasín MA, Gómez-Puerta JA, Plaza J, Pons-Estel G, et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the “CAPS Registry.” J Autoimmun. 2009; 32(3-4):240–5. doi.org/10.1016/j.jaut.2009.02.008
  6. Козловская Н.Л., Шилов Е.М., Метелева Н.А. и соавт. Клинические и морфологические особенности волчаночного нефрита при системной красной волчанке с антифосфолипидным синдромом. Терапевтический архив. 2006; №5:21-31 [Kozlovskaya N.L., Shilov E.M., Meteleva N.A. i soavt. Klinicheskie i morfologicheskie osobennosti volchanochnogo nefrita pri sistemnoi krasnoi volchanke s antifosfolipidnym sindromom. Terapevticheskii arkhiv. 2006; №5:21-31. (In Russ).]
  7. Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis. 2008; 68(6):1030–5. doi.org/10.1136/ard.2008.090670
  8. Salmon JE, Girardi G. The Role of Complement in the Antiphospholipid Syndrome. Complement in Autoimmunity . 2003;133–48. doi.org/10.1159/000075690
  9. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003; 112(11):1644–54. doi.org/10.1172/jci200318817
  10. Gropp K, Weber N, Reuter M, Micklisch S, Kopka I, Hallström T, et al. β2- glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood. 2011;118:2774–83. doi.org/10. 1182/blood-2011-02-339564
  11. Kitchens CS. Thrombotic Storm: When Thrombosis Begets Thrombosis. Am J Med. 1998; 104(4):381–5. doi.org/10.1016/s0002-9343(98)00061-8
  12. Blank M, Eisenstein M, Asherson RA, Cervera R, Shoenfeld Y. The Infectious Origin of the Antiphospholipid Syndrome. Infection and Autoimmunity. 2004;473–90. doi.org/10.1016/b978-044451271-0.50037-5
  13. Meroni P, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A, et al. Endothelial Activation by aPL: A Potential Pathogenetic Mechanism for the Clinical Manifestations of the Syndrome. J Autoimmun. 2000; 15(2):237–40. doi.org/10.1006/jaut.2000.0412
  14. Asherson R, Cervera R, de P, Erkan D, Boffa M-C, Piette J-C, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus.2003; 12(7):530–4.doi.org/10.1191/0961203303lu394oa
  15. Noris M, Remuzzi G. Atypical Hemolytic–Uremic Syndrome. N Engl J Med; 2009; 361(17):1676–87. doi.org/10.1056/nejmra0902814
  16. Лора Ш., Фремю-Бачи В. Атипичный гемолитико-уремический синдром. Нефрология. 2012;Том 16(№2): 16-46 [Lora Sh., Fremyu-Bachi V. Atipichnyi gemolitiko-uremicheskii sindrom. Nefrologiya.2012; Tom 16(№2): 16-46. (In Russ).]
  17. Cervera R. on behalf of the “CAPS Registry Project Group”. Catastrophic antiphospholipid syndrome (CAPS): update from the “CAPS Registry”. Lupus. 2010;19:412-418. doi: 10.1177/0961203309361353
  18. Med.ub.es. (2016). EuroLupus. [online] Available at: http://www.med.ub.es/MIMMUN/FORUM/CAPS.HTM
  19. Asherson RA, Cervera R. Microvascular and microangiopathic antiphospholipid-associated syndromes (“MAPS”). Autoimmun Rev. 2008; 7(3):164–7. doi.org/10.1016/j.autrev.2007.11.009
  20. Sciascia S, Cuadrado MJ, Khamashta M, Roccatello D. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014; 10(5):279–89. doi.org/10.1038/nrneph.2014.38
  21. Tsai H-M. A Mechanistic Approach to the Diagnosis and Management of Atypical Hemolytic Uremic Syndrome. Transfus Med Rev. 2014;28(4):187–97. doi.org/10.1016/j.tmrv.2014.08.004
  22. Asherson R.A. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson’s) syndrome. Immunobiology. 2005 (210):727–733. doi.org/10.1016/j.imbio.2005.10.002
  23. Larakeb A, Leroy S, Frémeaux-Bacchi V, Montchilova M, Pelosse B, Dunand O, et al. Ocular involvement in hemolytic uremic syndrome due to factor H deficiency—are there therapeutic consequences? Pediatr Nephrol. 2007; 22(11):1967–70. doi.org/10.1007/s00467-007-0540-0
  24. Kavanagh D, Richards A, Fremeaux-Bacchi V, Noris M, Goodship T, Remuzzi G, et al. Screening for Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome. Clin JAm Soc Nephrol. 2007; 2(3):591–6. doi.org/10.2215/cjn.03270906
  25. Bao L, Quigg RJ. Complement in Lupus Nephritis: The Good, the Bad, and the Unknown. Semin Nephrol. 2007 Jan;27(1):69–80. doi.org/10.1016/j.semnephrol.2006.09.009
  26. Козлов Л.В. Исследование функциональной активности компонентов и факторов системы комплемента человека. Вопросы медицинской химии. 2002; том 48 №6, с. 624-631. [Kozlov L.V. Issledovanie funktsional'noi aktivnosti komponentov i faktorov sistemy komplementa cheloveka. Voprosy meditsinskoĭ khimii. 2002; tom 48 №6,s. 624-631. (In Russ).]
  27. Melis JPM, Strumane K, Ruuls SR, Beurskens FJ, Schuurman J, Parren PWHI. Complement in therapy and disease. Mol Immunol. 2015; 67(2):117–30. doi.org/10.1016/j.molimm.2015.01.028
  28. Dragon-Durey M-A, Fremeaux-bacchi V, Loirat C et al. Heterozygous and Homozygous Factor H Deficiencies Associated with Hemolytic Uremic Syndrome or Membranoproliferative Glomerulonephritis: Report and Genetic Analysis of 16 Cases. J Am Soc Nephrol. 2004; 15(3):787–95. doi.org/10.1097/01.asn.0000115702.28859.a7
  29. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood . 2009; 115(2):379–87. doi.org/10.1182/blood-2009-05-221549
  30. Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006; 108 (4) : 1267–79. doi.org/10.1182/blood-2005-10-007252
  31. Hakobyan S, Harris CL, Tortajada A, Goicochea de Jorge E, Garci´a-Layana A, Ferna´ndez-Robredo P, et al. Measurement of Factor H Variants in Plasma Using Variant-Specific Monoclonal Antibodies: Application to Assessing Risk of Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2008; 49(5):1983-90.doi.org/10.1167/iovs.07-1523
  32. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey M-A, Ngo S, et al. Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults. Clin J Am Soc Nephrol. 2013; 8(4):554–62. doi.org/10.2215/cjn.04760512
  33. Breen KA, Seed P, Parmar K, Moore GW, Stuart-Smith SE, Hunt BJ. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost. 2012;107(3):423–9. doi.org/10.1160/th11-08-0554

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies